ARK Investment Management LLC lowered its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 38.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,823 shares of the company's stock after selling 61,802 shares during the period. ARK Investment Management LLC's holdings in Cellebrite DI were worth $2,177,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the business. Juncture Wealth Strategies LLC lifted its position in shares of Cellebrite DI by 0.8% during the fourth quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock worth $1,322,000 after purchasing an additional 505 shares in the last quarter. Strategic Advisors LLC lifted its holdings in Cellebrite DI by 3.4% during the 4th quarter. Strategic Advisors LLC now owns 29,082 shares of the company's stock worth $641,000 after buying an additional 950 shares in the last quarter. Quarry LP bought a new position in Cellebrite DI in the 3rd quarter valued at $27,000. Advisors Asset Management Inc. increased its stake in shares of Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after buying an additional 1,742 shares during the period. Finally, Venturi Wealth Management LLC raised its position in shares of Cellebrite DI by 28.6% during the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock worth $152,000 after acquiring an additional 2,000 shares during the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.
Cellebrite DI Stock Up 0.3 %
NASDAQ CLBT traded up $0.06 during trading on Friday, reaching $18.56. 3,566,309 shares of the stock traded hands, compared to its average volume of 2,188,033. The stock's 50-day moving average price is $22.31 and its 200 day moving average price is $19.61. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of -13.35, a price-to-earnings-growth ratio of 4.27 and a beta of 1.47. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Craig Hallum lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Friday, February 14th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $23.43.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
